Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 676 to 700 of 872

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	TA389	27 April 2016	27 April 2016
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis	TA386	23 March 2016	23 March 2016
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)	TA23	26 April 2001	3 March 2016
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia	TA385	24 February 2016	24 February 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma	TA384	18 February 2016	18 February 2016
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis	TA383	1 February 2016	1 February 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	TA377	27 January 2016	27 January 2016
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy	TA378	27 January 2016	27 January 2016
Nintedanib for treating idiopathic pulmonary fibrosis	TA379	27 January 2016	27 January 2016
Panobinostat for treating multiple myeloma after at least 2 previous treatments	TA380	27 January 2016	27 January 2016
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)	TA382	27 January 2016	27 January 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	TA375	26 January 2016	26 January 2016
Guidance on the use of imatinib for chronic myeloid leukaemia	TA70	22 October 2003	21 January 2016
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears	TA369	16 December 2015	16 December 2015
Bortezomib for previously untreated mantle cell lymphoma	TA370	16 December 2015	16 December 2015
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	TA373	16 December 2015	16 December 2015
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy	TA374	16 December 2015	16 December 2015
Ledipasvir–sofosbuvir for treating chronic hepatitis C	TA363	25 November 2015	25 November 2015
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C	TA365	25 November 2015	25 November 2015
Vortioxetine for treating major depressive episodes	TA367	25 November 2015	25 November 2015
Tolvaptan for treating autosomal dominant polycystic kidney disease	TA358	28 October 2015	28 October 2015
Idelalisib for treating chronic lymphocytic leukaemia	TA359	28 October 2015	28 October 2015
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)	TA362	28 October 2015	28 October 2015
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy	TA352	26 August 2015	26 August 2015
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)	TA353	26 August 2015	26 August 2015

Results per page

10
25
50
All